Compare Genuine Parts Company (GPC) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs Incyte Corporation — how do they compare? Genuine Parts Company trades at $132.6 (market cap $18.62B), while Incyte Corporation trades at $120.79 (market cap $24.54B). The key difference: Incyte Corporation is the larger of the two by market cap, and Genuine Parts Company pays a 3.15% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| GPC | INCY | |
|---|---|---|
Market Cap | $18.62B | $24.54B |
Sector | Consumer Cyclical | Health |
52-Week High | $149.26 | $129.93 |
52-Week Low | $92.47 | $81.61 |
Enterprise Value | $24.72B | $20.04B |
Dividend Yield | 3.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPC trades at $134.54, down 0.8% on the day, with a bullish technical outlook supported by moving averages despite overbought RSI readings. The company reported strong Q2 2026 earnings with EPS of $2.15 beating estimates of $2.08, while revenue grew 6% year-over-year to $6.5 billion. However, net income margin remains thin at 0.13% for 2025, though the P/S ratio of 0.75 suggests reasonable valuation relative to sales.
The stock offers a dividend yield supported by 70 years of increases, with analyst consensus target at $148.67 suggesting 10.5% upside. Key risks include compressed profit margins, rising debt levels, and sensitivity to automotive industry cycles. Institutional ownership shows mixed signals with some funds increasing positions while others trimmed holdings in Q1 2026.
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
